Brief: Fennec Pharmaceuticals Announces Settlement Agreement Resolving Pedmark Patent Litigation
16/03/2026 12:20
March 16 (Reuters) - Fennec Pharmaceuticals Inc FENC.O: FENNEC PHARMACEUTICALS ANNOUNCES SETTLEMENT AGREEMENT RESOLVING PEDMARK PATENT LITIGATION FENNEC PHARMACEUTICALS INC - CIPLA BARRED FROM MARKETING GENERIC SODIUM THIOSULFATE UNTIL SEPTEMBER 1, 2033 FENNEC PHARMACEUTICALS INC: UNDER TERMS OF SETTLEMENT, LAWSUIT WILL BE DISMISSED WITH EACH PARTY BEARING THEIR OWN COSTS Source text: ID:nGNX9TGBKl Further company coverage: FENC.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fennec Pharmaceuticals
See all newsFennec Pharmaceuticals Inc. reports results for the quarter ended June 30 - Earnings Summary
Fennec Pharmaceuticals Q2 sales rise on PEDMARK demand
Fennec Pharmaceuticals Inc. expected to post earnings of 1 cent a share - Earnings Preview
Fennec Pharmaceuticals Q1 sales rise 73% on PEDMARK demand
U.S. STOCKS ON THE MOVE-UnitedHealth, Intel, Apple